Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Status:
Recruiting
Trial end date:
2024-02-20
Target enrollment:
Participant gender:
Summary
This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of
ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy
for patients with multiple myeloma who have achieved at least partial response (PR) or better
after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.